



## RESMED INC. ANNOUNCES EXCHANGE RATE FOR UPCOMING DIVIDEND PAYMENT

---

SYDNEY, November 24, 2014 – ResMed Inc. (NYSE: RMD and ASX: RMD) announced today that the exchange rate for the dividend to be paid on December 18, 2014 to holders of CHESS Depositary Instruments (CDIs) trading on the Australian Securities Exchange (ASX) will be \$0.8622 U.S. dollars for \$1.00 Australian dollar. The dividend to be paid in Australian currency to CDI holders will be \$0.0325 Australian dollars per CDI.

ResMed previously declared on October 20, 2014 a dividend of \$0.28 U.S. dollars per share, for ResMed's common stock trading on the New York Stock Exchange (NYSE). The dividend will be paid in U.S. currency to holders of the common stock trading on the NYSE. Holders of CDIs trading on the ASX receive an equivalent amount in Australian currency, based on the exchange rate on the record date of November 20, 2014, and reflecting the 10:1 ratio between CDIs and NYSE shares.

### **About ResMed**

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit [www.resmed.com](http://www.resmed.com).

Further information can be obtained by contacting Agnes Lee at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the company's multilingual website at [www.resmed.com](http://www.resmed.com).

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products -- are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

- End -